lundi 1 juillet 2019

Onco Actu du 1er juillet 2019


1. BIOLOGIE



No tumour is an island [Cancer Research UK]










3.1 PRÉVENTION - TABAC



India asks its states not to partner with Philip Morris-funded foundation [Reuters]











3.1.1 PRÉVENTION - TABAC - E-CIGS



San Francisco vape ban could hinder war on tobacco, say UK experts [The Guardian]











Teen vaping on the rise in U.S, Canada [Reuters]











3.3 PRÉVENTION - VACCINS



Let’s End HPV-related Cancers: A Congressional Briefing [Cancer Research Catalyst]











3.3.2 PRÉVENTION - VACCINS (OBSERVATION)



HPV vaccination works. Period. [Respectful Insolence]











4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



Fake news putting 50,000 lesbian, gay and bisexual women at risk of cancer [NHS England]










Lesbian women cervical screening myth is 'dangerous' [BBC News]











4.9 DÉP., DIAG. & PRONO. - SEIN



Competing Breast Cancer Assays Beat Genomic Health's Oncotype Dx in Canadian Cost Modeling Study [Genome Web]











5.10 TRAITEMENTS - ESSAIS



Two-in-one drug combining Herceptin with chemotherapy keeps women’s breast cancers at bay [Institute of Cancer Research]











Basket Cases: How Real-World Testing for Drugs Approved Based on Basket Trials Might Lead to False Diagnoses, Patient Risks, and Squandered Resources [Journal of Clinical Oncology]










5.12.6 IMMUNOTHÉRAPIES - AMM



CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer [Roche]











EMA Recommends Extension of Indications for Atezolizumab [ESMO]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



Seducing Pfizer: How Array’s team patiently worked up the ladder to win an $11.4B bid from Albert Bourla [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Sequencing Firm Adaptive’s $300M IPO Comes With Pharma Ambitions [Xconomy]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019 [EMA]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



J&J's Darzalex pads blockbuster sales with another myeloma nod in new patients [Fierce Pharma]











Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr) [Pfizer]











Another Biosimilar Approval From FDA, Another Unknown Launch Date [RAPS]











Pfizer's Avastin biosimilar wins FDA approval [Reuters]











FDA approves daratumumab for multiple myeloma ineligible for autologous stem cell transplant [FDA]










6. LUTTE CONTRE LES CANCERS



ASCO Commends the National Academies of Sciences, Engineering, and Medicine for its Report on Guiding Cancer Control [ASCO]











National Cancer Control Efforts Should Address the System, Not Its Individual Parts, Says New Report [National Academies of Sciences, Engineering, and Medicine]










6.1 OBSERVATION



The first complete picture of how long it takes to diagnose cancer in England [Cancer Research UK]










6.10.1 POLITIQUES (USA)



Student loan borrowers with cancer are supposed to get a break from their bills. That’s not happening [CNBC]











6.11 PATIENTS



Luis Alvarez, Champion of 9/11 Responders, Dies at 53 [NY Times]











6.12 ETHIQUE



Pounds for Patients? How the private hospital sector uses financial incentives to win the business of medical consultants. [Center for Health and the Public Interest]











NHS oncologists are being offered shares in private hospitals. This must stop [The Guardian]











6.7 DMP, BIG DATA & APPLIS



Once 'bodies for hire,' CROs are finding a new role as data specialists [Biopharma Dive]











New programme to explore how innovation in health data can benefit everyone [Wellcome Trust]